Genome-wide analysis of gynecologic cancer: The cancer genome atlas in ovarian and endometrial cancer (Review)

Moito Iijima, Kouji Banno, Ryuichiro Okawa, Megumi Yanokura, Miho Iida, Takashi Takeda, Haruko Kunitomi-Irie, Masataka Adachi, Kanako Nakamura, Kiyoko Umene, Yuya Nogami, Kenta Masuda, Eiichiro Tominaga, Daisuke Aoki

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma. Genome-wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy-number low and genome copy-number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome-wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.

Original languageEnglish
Pages (from-to)1063-1070
Number of pages8
JournalOncology Letters
Volume13
Issue number3
DOIs
Publication statusPublished - 2017 Mar 1

Fingerprint

Atlases
Endometrial Neoplasms
Ovarian Neoplasms
Genome
Neoplasms
Mutation
1-Phosphatidylinositol 4-Kinase
Carcinoma
Genes
Proto-Oncogene Proteins c-akt
Microsatellite Instability
Proto-Oncogenes
Fibrosarcoma
Protein-Serine-Threonine Kinases
Sirolimus
Epigenomics
Sarcoma
Proteomics
Proteins
Breast Neoplasms

Keywords

  • AT-rich interaction domain 1A
  • Cancer genome atlas
  • Endometrial cancer
  • Ovarian cancer
  • Tumor protein 53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Genome-wide analysis of gynecologic cancer : The cancer genome atlas in ovarian and endometrial cancer (Review). / Iijima, Moito; Banno, Kouji; Okawa, Ryuichiro; Yanokura, Megumi; Iida, Miho; Takeda, Takashi; Kunitomi-Irie, Haruko; Adachi, Masataka; Nakamura, Kanako; Umene, Kiyoko; Nogami, Yuya; Masuda, Kenta; Tominaga, Eiichiro; Aoki, Daisuke.

In: Oncology Letters, Vol. 13, No. 3, 01.03.2017, p. 1063-1070.

Research output: Contribution to journalReview article

Iijima, M, Banno, K, Okawa, R, Yanokura, M, Iida, M, Takeda, T, Kunitomi-Irie, H, Adachi, M, Nakamura, K, Umene, K, Nogami, Y, Masuda, K, Tominaga, E & Aoki, D 2017, 'Genome-wide analysis of gynecologic cancer: The cancer genome atlas in ovarian and endometrial cancer (Review)', Oncology Letters, vol. 13, no. 3, pp. 1063-1070. https://doi.org/10.3892/ol.2017.5582
Iijima, Moito ; Banno, Kouji ; Okawa, Ryuichiro ; Yanokura, Megumi ; Iida, Miho ; Takeda, Takashi ; Kunitomi-Irie, Haruko ; Adachi, Masataka ; Nakamura, Kanako ; Umene, Kiyoko ; Nogami, Yuya ; Masuda, Kenta ; Tominaga, Eiichiro ; Aoki, Daisuke. / Genome-wide analysis of gynecologic cancer : The cancer genome atlas in ovarian and endometrial cancer (Review). In: Oncology Letters. 2017 ; Vol. 13, No. 3. pp. 1063-1070.
@article{01bc52c1c69248018974502a7338116a,
title = "Genome-wide analysis of gynecologic cancer: The cancer genome atlas in ovarian and endometrial cancer (Review)",
abstract = "Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma. Genome-wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy-number low and genome copy-number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome-wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.",
keywords = "AT-rich interaction domain 1A, Cancer genome atlas, Endometrial cancer, Ovarian cancer, Tumor protein 53",
author = "Moito Iijima and Kouji Banno and Ryuichiro Okawa and Megumi Yanokura and Miho Iida and Takashi Takeda and Haruko Kunitomi-Irie and Masataka Adachi and Kanako Nakamura and Kiyoko Umene and Yuya Nogami and Kenta Masuda and Eiichiro Tominaga and Daisuke Aoki",
year = "2017",
month = "3",
day = "1",
doi = "10.3892/ol.2017.5582",
language = "English",
volume = "13",
pages = "1063--1070",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - Genome-wide analysis of gynecologic cancer

T2 - The cancer genome atlas in ovarian and endometrial cancer (Review)

AU - Iijima, Moito

AU - Banno, Kouji

AU - Okawa, Ryuichiro

AU - Yanokura, Megumi

AU - Iida, Miho

AU - Takeda, Takashi

AU - Kunitomi-Irie, Haruko

AU - Adachi, Masataka

AU - Nakamura, Kanako

AU - Umene, Kiyoko

AU - Nogami, Yuya

AU - Masuda, Kenta

AU - Tominaga, Eiichiro

AU - Aoki, Daisuke

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma. Genome-wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy-number low and genome copy-number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome-wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.

AB - Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross-sectional genome-wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT-rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high-grade ovarian serous carcinoma, and Kirsten rat sarcoma and B-rapidly accelerated fibrosarcoma proto-oncogene, serine/threonine kinase gene mutations in low-grade ovarian serous carcinoma. Genome-wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy-number low and genome copy-number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP-ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome-wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.

KW - AT-rich interaction domain 1A

KW - Cancer genome atlas

KW - Endometrial cancer

KW - Ovarian cancer

KW - Tumor protein 53

UR - http://www.scopus.com/inward/record.url?scp=85011891358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011891358&partnerID=8YFLogxK

U2 - 10.3892/ol.2017.5582

DO - 10.3892/ol.2017.5582

M3 - Review article

AN - SCOPUS:85011891358

VL - 13

SP - 1063

EP - 1070

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 3

ER -